The purpose of the Sidney Kimmel Comprehensive Cancer Center (SKCCC) Cancer Functional Imaging Core is to provide state-of-the art noninvasive imaging capabilities to SKCCC members. Since its inception in 2005 this Core has significantly expanded and now includes a 9.4T horizontal bore magnet and a Kodak system, in addition to small animal PET and SPECT imaging systems as well as a Xenogen optical and VisualSonics ultrasound imaging system. This equipment is housed in a 2,400 sq. ft. small animal imaging facility in the Broadway Research Building (BRB) overseen by a full-time manager. These facilities form the Cancer Functional Imaging Core. Applications that are currently available using magnetic resonance imaging and spectroscopy and radionuclide imaging span molecular, cellular, preclinical human tumor model studies. To understand and exploit molecular pathways in cancer for therapeutic strategies, it is essential to detect and image the expression of these pathways, and determine the impact of this expression on function at the cellular level, as well In vivo. MR, radionuclide and optical techniques have a vast array of capabilities to characterize function. These imaging techniques are also easily translatable into the clinic, and are therefore compatible with 'bench to bedside'applications. Dr. Zaver M. Bhujwalla is the Director of the Cancer Functional Imaging Core. She is also Co-Program Leader of the SKCCC Cancer Molecular and Functional Imaging Program the Director of the JHU ICMIC (In vivo Cellular Molecular Imaging Center) Program and Associate Director of the JHU SAIRP (Small Animal Imaging Resource Program). Dr. Bhujwalla has an outstanding track record in MR molecular imaging applications in cancer. The two Associate Directors, Dr. Martin G. Pomper and Dr. Dmitri Artemov are well known investigators who have played a key role in the establishment of Molecular Imaging at JHU. Dr. Pomper is also Co- Leader of the SKCCC Cancer Molecular and Functional Imaging Program, Director of the JHU SAIRP and Associate Director of the JHU ICMIC. Lay: The Cancer Functional Imaging Core is a centralized resource that will assist investigators in the SKCCC with multi-modality imaging. The Core will also develop and implement new imaging technologies to advance cancer discovery and treatment.
| Zarif, Jelani C; Chalfin, Heather J; Pierorazio, Phillip M et al. (2018) Characterization of the Macrophage Infiltrate in a Case of Xanthogranulomatous Pyelonephritis. J Clin Urol 11:226-228 |
| Rowe, Steven P; Luber, Brandon; Makell, Monique et al. (2018) From validity to clinical utility: the influence of circulating tumor DNA on melanoma patient management in a real-world setting. Mol Oncol 12:1661-1672 |
| Martin, Allison M; Nirschl, Christopher J; Polanczyk, Magda J et al. (2018) PD-L1 expression in medulloblastoma: an evaluation by subgroup. Oncotarget 9:19177-19191 |
| Yeruva, Sri Lakshmi Hyndavi; Javadi, Mehrbod Som; Stearns, Vered (2018) Complete Response to Single-agent Palbociclib in Metastatic Breast Cancer: A Case Report. Clin Breast Cancer 18:e277-e280 |
| McDevitt, Michael R; Thorek, Daniel L J; Hashimoto, Takeshi et al. (2018) Feed-forward alpha particle radiotherapy ablates androgen receptor-addicted prostate cancer. Nat Commun 9:1629 |
| Shah, Tariq; Krishnamachary, Balaji; Wildes, Flonne et al. (2018) Molecular causes of elevated phosphoethanolamine in breast and pancreatic cancer cells. NMR Biomed 31:e3936 |
| Chung, Liam; Thiele Orberg, Erik; Geis, Abby L et al. (2018) Bacteroides fragilis Toxin Coordinates a Pro-carcinogenic Inflammatory Cascade via Targeting of Colonic Epithelial Cells. Cell Host Microbe 23:203-214.e5 |
| LaFleur, Martin W; Muroyama, Yuki; Drake, Charles G et al. (2018) Inhibitors of the PD-1 Pathway in Tumor Therapy. J Immunol 200:375-383 |
| Handy, Catherine E; Antonarakis, Emmanuel S (2018) Sipuleucel-T for the treatment of prostate cancer: novel insights and future directions. Future Oncol 14:907-917 |
| Popovic, Aleksandra; Jaffee, Elizabeth M; Zaidi, Neeha (2018) Emerging strategies for combination checkpoint modulators in cancer immunotherapy. J Clin Invest 128:3209-3218 |
Showing the most recent 10 out of 2393 publications
